Ameriprise
ETNB

Ameriprise’s 89bio ETNB Stock Holding History

Ameriprise’s Portfolio ETNB Stock Details ETNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-255,623
Closed -$3.76M – 4114
2025
Q3 		$3.76M Buy
255,623
+117,213
+85% +$1.19M ﹤0.01% 2634
2025
Q2 		$1.36M Buy
+138,410
New +$1.15M ﹤0.01% 3138
2025
Q1 		– Sell
-28,230
Closed -$221K – 4056
2024
Q4 		$221K Buy
28,230
+14,641
+108% +$121K ﹤0.01% 3833
2024
Q3 		$101K Buy
+13,589
New +$114K ﹤0.01% 3836
2023
Q4 		– Sell
-346,946
Closed -$5.36M – 3918
2023
Q3 		$5.36M Sell
346,946
-36,145
-9% -$607K ﹤0.01% 2224
2023
Q2 		$7.26M Buy
383,091
+131,107
+52% +$2.3M ﹤0.01% 2054
2023
Q1 		$3.84M Buy
+251,984
New +$3.29M ﹤0.01% 2488

Other funds holding ETNB

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ameriprise's ETNB Position: Q4 2025 in Review

Ameriprise sold out of 89bio (ETNB) in Q4 2025, closing a stake of 255,623 shares — an estimated $3.76M sold.

Ameriprise first reported a position in ETNB in Q1 2023 and held it in 7 quarters. The position peaked at $7.26M in Q2 2023. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • Ameriprise reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 255,623 89bio shares in Q4 2025, an estimated $3.76M.
  • Ameriprise first reported a position in 89bio in Q1 2023 and held it in 7 quarters.
  • Ameriprise's 89bio position peaked at $7.26M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.